New England Journal of Medicine, Ahead of Print.
NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
Read More →
Novembre 2024
Risultati per: NEJM
Questo è quello che abbiamo trovato per te
NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction
New England Journal of Medicine, Ahead of Print.
Read More →
Novembre 2024
NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
New England Journal of Medicine, Ahead of Print.
Read More →
Novembre 2024
NEJM at AHA — Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
New England Journal of Medicine, Ahead of Print.
Read More →
Novembre 2024
NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
New England Journal of Medicine, Ahead of Print.
Read More →
Novembre 2024
NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
New England Journal of Medicine, Ahead of Print.
Read More →
Novembre 2024
NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
New England Journal of Medicine, Ahead of Print.
Read More →
Novembre 2024
NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Ponsegromab in Cancer Cachexia
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
New England Journal of Medicine, Ahead of Print.
Read More →
Settembre 2024
